Anavex Life Sciences Corporation

NASDAQ:AVXL   3:59:56 PM EDT
18.26
-3.10 (-14.51%)
4:02:56 PM EDT: $18.29 +0.03 (+0.16%)
Products, Regulatory

Anavex Life Sciences Announces Anavex2-73 (Blarcamesine) Biomarker Correlated With Efficacy Endpoints In Placebo-Controlled U.S. Phase 2 Clinical Trial For The Treatment Of Adult Patients With R

Published: 06/21/2021 11:54 GMT
Anavex Life Sciences Corporation (AVXL) - Anavex Life Sciences Announces Anavex®2-73 (blarcamesine) Biomarker Correlated With Efficacy Endpoints in Placebo-controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients With Rett Syndrome.
Anavex Life Sciences Corp - Outcome of Trial is "very Promising" in Terms of Both Safety and Clinical Improvement.
Anavex Life Sciences Corp - Anavex is Planning to Meet With FDA to Discuss Approval Pathway.